ATE160341T1 - Benzolsulfonamid-derivate und verfahren zur herstellung - Google Patents

Benzolsulfonamid-derivate und verfahren zur herstellung

Info

Publication number
ATE160341T1
ATE160341T1 AT94119833T AT94119833T ATE160341T1 AT E160341 T1 ATE160341 T1 AT E160341T1 AT 94119833 T AT94119833 T AT 94119833T AT 94119833 T AT94119833 T AT 94119833T AT E160341 T1 ATE160341 T1 AT E160341T1
Authority
AT
Austria
Prior art keywords
group
substituted
unsubstituted
formula
single bond
Prior art date
Application number
AT94119833T
Other languages
English (en)
Inventor
Koichiro Yamada
Kosuke Yasuda
Kohei Kikkawa
Rikako Kohno
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Application granted granted Critical
Publication of ATE160341T1 publication Critical patent/ATE160341T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69Benzenesulfonamido-pyrimidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT94119833T 1993-12-17 1994-12-15 Benzolsulfonamid-derivate und verfahren zur herstellung ATE160341T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP31877993 1993-12-17
JP14062894 1994-06-23
JP18355394 1994-08-04

Publications (1)

Publication Number Publication Date
ATE160341T1 true ATE160341T1 (de) 1997-12-15

Family

ID=27318092

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94119833T ATE160341T1 (de) 1993-12-17 1994-12-15 Benzolsulfonamid-derivate und verfahren zur herstellung

Country Status (17)

Country Link
US (2) US5589478A (de)
EP (1) EP0658548B1 (de)
KR (1) KR100250176B1 (de)
CN (1) CN1051544C (de)
AT (1) ATE160341T1 (de)
AU (1) AU676620B2 (de)
CA (1) CA2137953C (de)
DE (1) DE69406900T2 (de)
DK (1) DK0658548T3 (de)
ES (1) ES2111237T3 (de)
FI (1) FI115137B (de)
GR (1) GR3025855T3 (de)
HK (1) HK1004333A1 (de)
IL (1) IL111959A (de)
MY (1) MY130908A (de)
SG (1) SG52234A1 (de)
TW (1) TW430661B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
ES2180664T3 (es) * 1994-12-20 2003-02-16 Hoffmann La Roche Derivados de aril- y heteroarilsulfonamida, obtencion y uso de los mismos en calidad de antagonistas de endotelina.
TW313568B (de) * 1994-12-20 1997-08-21 Hoffmann La Roche
CA2207100C (en) 1994-12-28 2008-02-19 Kowa Co., Ltd. Pyrimidine derivatives
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US5883092A (en) * 1995-09-06 1999-03-16 Kowa Co., Ltd. Pyrimidine derivatives as endothelin antagonists
CZ260596A3 (en) * 1995-10-12 1997-12-17 Hoffmann La Roche Sulfonamide derivative, process of its preparation and pharmaceutical composition containing thereof
ATE201202T1 (de) * 1995-12-20 2001-06-15 Yamanouchi Pharma Co Ltd Arylethensulfonamid-derivate und diese enthaltende medikamente
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5958905A (en) 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
CN1067821C (zh) * 1997-03-13 2001-06-27 倚天资讯股份有限公司 一种互联网实时广播装置及其方法
PL197843B1 (pl) 1997-04-28 2008-05-30 Encysive Pharmaceuticals Inc Farmaceutycznie dopuszczalne sole metali alkalicznych ze związkami sulfonoamidowymi, środek farmaceutyczny, zastosowanie farmaceutycznie dopuszczalnych soli metali alkalicznych ze związkami sulfonoamidowymi, sposób wytwarzania liofilizowanego proszku i sposób wytwarzania farmaceutycznie dopuszczalnych soli metali alkalicznych ze związkami sulfonoamidowymi
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
KR100388506B1 (ko) 1998-03-31 2003-06-25 다나베 세이야꾸 가부시키가이샤 배뇨장애의 예방·치료제
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6417185B1 (en) 1998-06-19 2002-07-09 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
GB0013368D0 (en) * 2000-05-31 2000-07-26 Pfizer Ltd Enzymatic oxidations
AU2001263850A1 (en) * 2000-04-20 2001-11-07 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity
AU2001265871A1 (en) * 2000-04-25 2001-11-07 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
US6610518B2 (en) 2000-05-31 2003-08-26 Pfizer Inc. Enzymatic oxidations
US6387915B2 (en) 2000-05-31 2002-05-14 Pfizer Inc. Isoxazole-sulfonamide endothelin antagonists
CA2348847A1 (en) * 2000-05-31 2001-11-30 Pfizer Inc. New isoxazole-sulfonamide endothelin antagonists
MY140724A (en) * 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US20020091114A1 (en) 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
WO2003099773A1 (en) 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
AU2011218661B2 (en) * 2002-05-24 2012-07-05 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US7420055B2 (en) * 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US20070021466A1 (en) * 2002-11-18 2007-01-25 Solomon Ungashe CCR2 inhibitors and methods of use thereof
ATE517102T1 (de) * 2002-11-18 2011-08-15 Chemocentryx Inc Arylsulfonamide
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7227035B2 (en) * 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
ATE423103T1 (de) 2002-12-02 2009-03-15 Actelion Pharmaceuticals Ltd Pyrimidin-sulfonamide und ihre verwendung als endothelin-rezeptor-antagonisten
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
DK1725540T5 (da) 2004-03-05 2012-10-22 Hoffmann La Roche Diaminopyrimidiner som p2x3- og p2x2/3-antagonister
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
CA2619919C (en) 2005-09-01 2014-04-01 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
EP1924566B1 (de) 2005-09-01 2016-01-13 F.Hoffmann-La Roche Ag Diaminopyrimidine als p2x3- und p3x2/3-modulatoren
CN101253159B (zh) 2005-09-01 2011-12-07 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物
US20100022568A1 (en) * 2006-04-13 2010-01-28 Actelion Pharmaceeuticals Ltd. Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
ATE530531T1 (de) * 2007-12-18 2011-11-15 Dipharma Francis Srl Verfahren zur herstellung von bosentan
US8541431B2 (en) * 2008-05-19 2013-09-24 The University Of Tennessee Research Foundation Pyrimidine non-classical cannabinoid compounds and related methods of use
US20110263623A1 (en) * 2008-08-12 2011-10-27 Cadila Healthcare Limited Process for preparation of bosentan
WO2011078143A1 (ja) * 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
WO2014093230A2 (en) * 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
WO2019054944A1 (en) * 2017-09-12 2019-03-21 Agency For Science, Technology And Research COMPOUNDS USEFUL AS INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANFERASE
CN107778254A (zh) * 2017-12-07 2018-03-09 陈国妃 抗病毒药物中间体氧代二嘧啶衍生物的合成方法
CN118201908A (zh) * 2021-11-08 2024-06-14 正大天晴药业集团股份有限公司 氮杂联苯类化合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545944A1 (de) * 1964-06-19 1969-12-11 Hoffmann La Roche Verfahren zur Herstellung von neuen Sulfonamiden der Pyrimidinreihe
TW270116B (de) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
TW287160B (de) * 1992-12-10 1996-10-01 Hoffmann La Roche

Also Published As

Publication number Publication date
FI945900A0 (fi) 1994-12-15
KR100250176B1 (ko) 2000-09-01
MY130908A (en) 2007-07-31
ES2111237T3 (es) 1998-03-01
AU676620B2 (en) 1997-03-13
US5728706A (en) 1998-03-17
DK0658548T3 (da) 1998-03-16
AU8046194A (en) 1995-06-22
SG52234A1 (en) 1998-09-28
DE69406900T2 (de) 1998-04-09
IL111959A (en) 2000-07-16
CA2137953C (en) 2002-03-26
HK1004333A1 (en) 1998-11-20
EP0658548B1 (de) 1997-11-19
TW430661B (en) 2001-04-21
CN1111242A (zh) 1995-11-08
CN1051544C (zh) 2000-04-19
CA2137953A1 (en) 1995-06-18
FI945900A (fi) 1995-06-18
KR950017972A (ko) 1995-07-22
IL111959A0 (en) 1995-06-29
GR3025855T3 (en) 1998-04-30
US5589478A (en) 1996-12-31
EP0658548A1 (de) 1995-06-21
FI115137B (fi) 2005-03-15
DE69406900D1 (de) 1998-01-02

Similar Documents

Publication Publication Date Title
ATE160341T1 (de) Benzolsulfonamid-derivate und verfahren zur herstellung
DE69321525D1 (de) Morphinan-derivate und medizinische verwendung
ATE150462T1 (de) Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung
DK0622361T3 (da) Heterocykliske forbindelser som bradykininantagonister
PT1159279E (pt) 4-oxo-4,7-di-hidrotieno¬2,3-b|piridino-5-carboxamidas como agentes antivirais
DE60004217D1 (de) Sulphostinanaloga und verfahren zur herstellung von sulphostin und analoga davon
ATE146473T1 (de) Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung
IL97161A0 (en) Thiazine and oxazine derivatives,their preparation and pharmaceutical compositions containing them
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
ATE81655T1 (de) Cephemverbindungen und verfahren zu ihrer herstellung.
DE3586649D1 (de) Verwendung von spergualinderivaten zur herstellung von arzneimitteln mit immunodepressiver wirkung.
NO921159L (no) Tiazolidinon- og oksazolidinonderivater, fremgangsmaate til fremstilling derav, samt anvendelse av derivatene som vasodilatorer
ATE41659T1 (de) Benzothiazepinderivate, verfahren zur herstellung und pharmazeutische zusammensetzungen.
DK0420224T3 (da) Anthihepatopatisk middel
EP0726269A4 (de) Quinolincarbonsäurederivat une seine salze
DE69327077T2 (de) Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen
ATE81466T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur prophylaxe und zur behandlung von herzinsuffizienz.
ATE79259T1 (de) Prophylaktische und heilende zusammensetzung enthaltende eine 8-chlorbenzothiazepin-verbindung und dessen verwendung.
DE3782229D1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
IL110369A0 (en) Pharmaceutical compositions for the prevention and/or treatment of gastrointestinal diseases including ulcer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee